Table 2.
Multivariate CRC-specific survival analysis of different clinical stages in CRC patients with different sites
| Cecum | Ascending colon HR (95% CI) | Transverse colon HR (95% CI) | Descending colon HR (95% CI) | Sigmoid colon HR (95% CI) | Rectum HR (95% CI) | |
|---|---|---|---|---|---|---|
| Stage at presentation | ||||||
| Stage 0 | 1.00 | 0.64 (0.48–0.85)* | 1.18 (0.8–1.74) | 1.25 (0.91–1.74) | 0.98 (0.69–1.4) | 1.14 (0.71–1.84) |
| Stage I | 1.00 | 0.58 (0.54–0.61)** | 0.86 (0.79–0.93)** | 1.07 (1–1.15)* | 1.03 (0.95–1.1) | 1.05 (0.96–1.16) |
| Stage II | 1.00 | 0.57 (0.54–0.6)** | 0.78 (0.73–0.84)** | 1 (0.95–1.06) | 0.94 (0.89–0.99)* | 0.91 (0.85–0.98)* |
| Stage III | 1.00 | 0.55 (0.52–0.58)** | 0.81 (0.75–0.87)** | 1.1 (1.03–1.18)* | 0.98 (0.91–1.05) | 0.87 (0.8–0.95)* |
| Stage IV | 1.00 | 0.58 (0.5–0.66)** | 0.88 (0.75–1.04) | 1.11 (0.96–1.28) | 1.07 (0.92–1.24) | 0.94 (0.78–1.13) |
| All stages | 1.00 | 0.56 (0.54–0.57)** | 0.82 (0.78–0.85)** | 1.07 (1.04–1.11)** | 0.98 (0.95–1.02) | 0.94 (0.89–0.98)* |
** p < 0.001, *p < 0.05; CI confidence interval, HR hazard ratio. The classification criteria of stages refer to the AJCC/UICC TNM staging system. The cecum cancer group was set to 1 as the control group